Capstone Therapeutics Corp represents values of innovation, integrity, and growth. With a corporate philosophy focused on advanced medical research and development, Capstone is dedicated to creating life-changing therapies for patients worldwide. The company emphasizes a commitment to scientific excellence and collaboration, driving its pursuit of breakthrough treatments in areas such as orphan diseases and regenerative medicine. Capstone Therapeutics Corp believes in the power of cutting-edge technology and strategic partnerships to drive success and deliver value to its stakeholders. Through its visionary approach, Capstone aims to revolutionize healthcare and improve patients' lives globally.

Capstone Therapeutics Corp primarily operates in the United States.

Capstone Therapeutics Corp has achieved several significant milestones. One notable achievement includes the completion of Phase 1 clinical trials for their lead product candidate, AZX100. Additionally, the company has successfully secured several important patents and intellectual property rights related to their innovative drug delivery platform technologies. Furthermore, Capstone Therapeutics Corp has also formed strategic collaborations and partnerships with renowned healthcare organizations to further enhance their research and development efforts. These milestones demonstrate the company's commitment to advancing medical innovation and their potential for long-term growth in the biopharmaceutical industry.

Capstone Therapeutics Corp is a pharmaceutical company headquartered in Tempe, Arizona. Founded in 1987, Capstone Therapeutics focuses on the development and commercialization of novel therapeutics in the field of biotechnology. The company primarily engages in the research and development of peptide-based drugs for various medical conditions, including metabolic diseases, such as diabetes and obesity. Capstone Therapeutics has a strong commitment to advancing medical science and has been actively involved in several clinical trials and collaborative research programs. With its extensive expertise and dedication to innovation, Capstone Therapeutics Corp continues to make significant contributions to the field of biopharmaceuticals.

The main competitors of Capstone Therapeutics Corp in the market include companies such as Amgen Inc., Pfizer Inc., Novartis AG, and Johnson & Johnson.

Capstone Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.

Capstone Therapeutics Corp operates in the biotechnology industry, focusing on the development of novel therapeutic peptides for the treatment of serious medical conditions. The company's business model revolves around leveraging its expertise in peptide biology and targeting specific disease pathways to develop innovative drug candidates. Through extensive research and clinical trials, Capstone Therapeutics Corp aims to develop highly effective and safe peptide-based treatments. By focusing on this specialized field, the company seeks to bring novel and potentially life-changing therapies to patients in need. Capstone Therapeutics Corp's business model emphasizes scientific expertise, innovation, and the pursuit of breakthrough treatments in the biotechnology sector.

Capstone Therapeutics için şu anki KGV hesaplanamıyor.

Capstone Therapeutics için mevcut KUV şu anda hesaplanamıyor.

Capstone Therapeutics için AlleAktien Kalite Skoru 3/10'dur.

Capstone Therapeutics için şu an ciro hesaplanamıyor.

Capstone Therapeutics için şu anda kar hesaplanamıyor.

Capstone Therapeutics Corp is a biotechnology company focused on developing therapies for the treatment of diseases. They have three main business areas: therapeutic development, diagnostic development, and intellectual property licensing. The development of therapeutics is Capstone's largest business area. They are working on several therapy projects, including AZX100 and CTP-656. AZX100 is an experimental drug for the treatment of fibrosis, currently being investigated in clinical Phase IIa. CTP-656 is a therapeutic for the treatment of cystic fibrosis and uses a novel formulation of Ivacaftor, an already approved drug for cystic fibrosis treatment. Capstone has also developed a promising diagnostic platform based on the identification of protein biomarkers. These can be used for early detection and monitoring of diseases such as Alzheimer's, cancer, and cardiovascular diseases. They are currently working with partners to further develop this platform and create diagnostic tests. Another important business area for Capstone is intellectual property licensing. They hold several patents based on biotechnological discoveries, covering various aspects of medical research and therapy development. They market these patents by selling licenses to other companies and research institutions. Capstone Therapeutics Corp also has partnerships with other companies and research institutions. They collaborate with New York University on the development of therapeutics for cardiovascular diseases and with the University of Alabama on the development of therapeutics against cancer. These partnerships allow the company to expand its research and development capabilities. Capstone's business model is based on the development of therapeutics and diagnostics, intellectual property licensing, and collaboration with other companies and research institutions. Their products and services aim to detect and treat diseases earlier. By developing new therapeutics and diagnostics and commercializing patents, the company aims to increase its revenue and strengthen its position in the biotechnology industry.

Capstone Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Capstone Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Capstone Therapeutics şirketinin ISIN kodu US14068E2081’dir.

Capstone Therapeutics 'nin WKN'si A2PRWA 'dir.

Capstone Therapeutics için Ticker CAPS’dir.

Son 12 ay içerisinde Capstone Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Capstone Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Capstone Therapeutics şirketinin mevcut temettü verimi .

Capstone Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Capstone Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Capstone Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son Capstone Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 21.12.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 21.12.2024 olarak gerçekleşti.

2023 yılında Capstone Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

Capstone Therapeutics hisselerinin temettüleri USD olarak dağıtılır.